Prediction of efficacy of octreotide therapy in patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2356-2362

  Colao, Annamaria ^a   Ferone, Diego ^a   Lastoria, Secondo ^b   Marzullo, Paolo ^a   Cerbone, Gaetana ^a   Di Sarno, Antonella ^a   Longobardi, Salvatore ^a   Merola, Bartolomeo ^a   Salvatore, Marco ^b   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

ABDOMINAL PAIN; ACCURACY; ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACROMEGALY; ADOLESCENT; ADULT; FEMALE; FORECASTING; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 8944244531     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.6.2356     Document Type: Article

References (16)

1. Lamberts SWJ. 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 9:417-436.
2. Sassolas G, Harris AG, James-Deidier A, French SMS 201-995 acromegaly study group. 1990 Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 53 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
3. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicentric acromegaly study group. Arch Intern Med. 151:1573-1578.
4. Ezzat S, Snyder PJ, Young WF, et al. 1992 Octreotide treatment of acromegaly. A randomized, multicentric study. Ann Intern Med. 117:711-718.
5. Lamberts SWJ, Uitterlinden P, Schuijff PC, Klijn JG. 1988 Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical cure. Clin Endocrinol (Oxf). 29:411-420.
6. Pieters GFFM, Smals AGH, Kloppenborg PWC. 1986 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. (letter) N Engl J Med. 314:1391.
7. Lamberts SWJ, Uitterlinden P, Del Pozo E. 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 65:703-710.
8. Lombardi G, Colao A, Ferone D, et al. 1995 CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol. 132:559-564.
9. Colao A, Merola B, Ferone D, et al. 1995 The acute test with octreotide is predictive of the chronic responsiveness to the drug in acromegalic patients. Program of the 77th Annual Meeting of The Endocrine Society, Washington DC, 1995 (Abstract P1-63).
10. Timsit J, Chanson P, Harris AG, et al. 1991 Short-term continuous infusion of octreotide in acromegaly. Horm Metab Res. 23:48-49.
11. Reubi JC, Heitz PU, Landolt AM. 1987 Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses. J Clin Endocrinol Metab. 65:65-73.
12. Lamberts SWJ, Krenning EP, Reubi JC. 1990 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 12:450-481.
13. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 20:716-731.
14. 111In-pentatreotide. Clin Endocrinol. 38:501-506.
15. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe H-J. 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 79:1416-1423.
16. Colao A, Lastoria S, Ferone D, et al. 1994 Pituitary imaging with Indium-111 octreotide (In-111-OCT) can predict the response to chronic OCT therapy. Eur J Endocrinol. [Suppl] 130:184 (Abstract).